Host: John J. Russell, MD

Guest: Emma Guttman-Yassky, MD, PhD

Building upon recent breakthroughs in our understanding of the pathologic mechanisms driving atopic dermatitis (AD), the existing pharmacopoeia is preparing for possible approval by the United States Food and Drug Administration of novel therapies that narrowly target immune dysregulation in moderate-to-severe disease. As a result, clinicians need to be knowledgeable about how these emerging agents modulate immune response in AD, as well as understand the clinical trial data regarding their use in patients with moderate-to-severe disease. Thus, clinicians who treat patients with this condition can be prepared to incorporate emerging therapies into treatment plans for appropriate patients as they become available. As a value added-resource, a specialized toolkit will also be included as a supplement to the webcast. The toolkit will provide for clinicians the latest treatment guidelines and updated reference guide. In addition, the toolkit will provide helpful information and resources for families and caregivers.